

This transcript of the Advisory Board on Radiation and Worker Health, Fernald Work Group, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Fernald Work Group for accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL 1
NATIONAL INSTITUTE FOR OCCUPATIONAL
SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND
WORKER HEALTH

+ + + + +

WORK GROUP ON FERNALD

+ + + + +

THURSDAY
APRIL 19, 2012

+ + + + +

The Work Group convened
telephonically at 11:00 a.m., Bradley P.
Clawson, Chairman, presiding.

PRESENT:

BRADLEY P. CLAWSON, Chairman
PAUL L. ZIEMER, Member

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

This transcript of the Advisory Board on Radiation and Worker Health, Fernald Work Group, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Fernald Work Group for accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

ALSO PRESENT:

2

TED KATZ, Designated Federal Official
ISAF AL-NABULSI, DOE
SANDRA BALDRIDGE
BOB BARTON, SC&A
EVERETT "RAY" BEATTY, SR.
ELIZABETH BRACKETT, ORAU Team
MEL CHEW, ORAU
SAM GLOVER, DCAS
STU HINNEFELD, DCAS
KARIN JESSEN, ORAU Team
JENNY LIN, HHS
JOYCE LIPSZTEIN, SC&A
JOHN MAURO, SC&A
ROBERT MORRIS, ORAU Team
MARK ROLFES, DCAS
BILLY SMITH, ORAU Team
JOHN STIVER, SC&A

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

This transcript of the Advisory Board on Radiation and Worker Health, Fernald Work Group, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Fernald Work Group for accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

T-A-B-L-E O-F C-O-N-T-E-N-T-S

Page 3

SC&A Response on In Vivo Thorium Bioassay 5
Methods (White Paper)
by John Stiver

Work Group Plans for April 26 Board 103
Teleconference

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 P-R-O-C-E-E-D-I-N-G-S 4

2 (11:00 a.m.)

3 MR. KATZ: Let me get this
4 started. This is the Advisory Board on
5 Radiation and Worker Health, Fernald Work
6 Group and we will begin roll call.

7 (Roll call.)

8 MR. KATZ: Let me just mention
9 this for everyone involved. Some of the
10 papers, I think, are already posted on the
11 website for this meeting.

12 There are a couple papers from
13 DCAS, they're not yet posted, they may be
14 posted now, but they were sent, Sandra, to you
15 directly by email by the program since they
16 hadn't been posted yet, so I hope you have
17 those, Sandra. One of those was a
18 presentation, a PowerPoint presentation that I
19 think DCAS will probably be using during this
20 meeting, as well as, again, the agenda for
21 this meeting is also on the website. It's a

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealgross.com

1 pretty simple agenda. 5

2 Now, I drafted this agenda without
3 input just by seeing the materials that were
4 flowing back and forth between the parties,
5 but the Chair and DCAS didn't have an
6 opportunity, or didn't get around to
7 commenting on the agenda, so I guess it's your
8 agenda.

9 Brad, if you wish to admit
10 revisions or solicit them from the program,
11 that'd be the place to start, I think. And,
12 everybody, please, other than the people who
13 are speaking, mute your phones. If you don't
14 have a mute button, use *6.

15 There's quite a lot of hiss in the
16 background, which makes me think there are a
17 lot of people that are not on mute. And then
18 to take your phone off of mute, just press *6
19 again. Okay, Brad, it's your meeting.

20 CHAIRMAN CLAWSON: Well, I
21 appreciate that and I'm trying to find my

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 agenda that I just dialed in on. It's
2 terrible when you do that, but I guess,
3 basically, I'll turn it over to John Stiver.
4 He's the SC&A person on this and we'll start
5 out from there.

6 MR. STIVER: Okay. Thank you,
7 Brad. My name is John Stiver from SC&A. I
8 know most of you all. Today's topic is fairly
9 focused. This is our issue 6b, which is the
10 in vivo chest count data issue for the period
11 of 1968 to 1978 when the data were reported in
12 units of -- milligrams thorium.

13 So a bit of a recap. At our last
14 meeting we had, kind of, come to a position
15 where, this was on February 9th, SC&A had
16 presented our kind of final position on this.

17 And that was that we felt that,
18 because of uncertainties in the data set,
19 which could, we felt, depending on how the
20 milligram data were calculated, could give
21 rise to underestimates up to possibly a factor

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 of 100 and also overestimates for the
2 unexposed contingent, which could approach a
3 factor of three orders of magnitude.

4 We felt that this data set was
5 just not adequate for reconstructing doses
6 with sufficient accuracy in an SEC context.

7 And shortly thereafter, NIOSH,
8 right before the Board meeting in Oakland,
9 they had posted some additional documents
10 which were related to this issue, some of
11 which, many of which we had already seen and I
12 believe there were a couple that we hadn't
13 seen.

14 And then, at the meeting, I
15 presented kind of a summary of our position.
16 I looked at two issues, really. One was the
17 uncertainties inherent in the data themselves
18 and we also looked at this, kind of, an
19 overarching issue.

20 This idea of whether the system
21 was adequate for the intended purpose under

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 EEOICPA, which was the issue of the stated
2 detection limit being so high as to result in
3 almost a de facto SEC-type situation where
4 almost, virtually all metabolic cancers would
5 likely be compensated.

6 And that's, really kind of an SEC
7 Subcommittee issue. I tuned in to the meeting
8 yesterday and the Board was taking a very
9 deliberate approach on this issue of
10 sufficient accuracy and what it really means
11 and how it should be defined.

12 And that's probably, you know, the
13 best way to approach this. And DCAS is in the
14 process, evidently, of putting together a
15 matrix of all SEC decisions and their bases,
16 and then that's going to kind of serve as a
17 starting point, kind of a gold standard.

18 And so that second aspect of
19 sufficient accuracy regarding the system
20 itself, I think, will be tabled today. I
21 really don't intend to discuss that because it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 really is more of a program-wide issue. 9

2 So what we're going to talk about,
3 really, is this issue of the particular data
4 set itself and the problems we have with it.

5 Since the Board meeting, Joyce
6 Lipsztein put together kind of a summary of
7 all the new NIOSH references as well as the
8 previous White Papers going back until, I
9 believe, August of 2011 and kind of laid out
10 what we feel are the SEC issues and the
11 technical bases for those.

12 And after that, I believe it was
13 April 9th, DCAS submitted a presentation
14 outlining their position in a nice spreadsheet
15 with links to the different documents that
16 kind of support the positions on the various
17 slides.

18 And one thing that really jumped
19 out on that list was an interview with L. Max
20 Scott. He was the principal architect of the
21 mobile system at Y-12 and evidently he's still

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 active and a professor at Louisiana State¹⁰
2 University, I believe.

3 And so they interviewed him and
4 clarified some of the issues for us, but
5 unfortunately, also crystallized some of the
6 problems that we saw in the data set.

7 But Mark Rolfes also put together
8 a presentation outlining their position, and I
9 guess the best way to approach this would be
10 to have Mark go ahead and give his
11 presentation and then we can talk about the
12 issues that we have with the derivations for
13 the milligrams thorium as they stand now.

14 MR. ROLFES: Okay, this is Mark
15 Rolfes. Thank you, John. Yes, I just put
16 together a brief slide show on bounding
17 thorium-232 intakes using the mobile in vivo
18 radiation monitoring laboratory data.

19 NIOSH can bound thorium-232
20 intakes -- I'm just going to go ahead and read
21 through these slides for people who don't have

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 it in front of them. 11

2 NIOSH can bound thorium-232
3 intakes. Sufficient data are available. A
4 coworker model has been developed using more
5 than 5000 mobile in vivo radiation monitoring
6 laboratory thorium chest count results.

7 Chronic thorium-232 intake
8 retention fractions were derived, which
9 account for the differential biokinetics of
10 decay products. And sample intake and dose
11 calculations have been completed to
12 demonstrate the methodology and feasibility of
13 the methodology.

14 NIOSH has investigated where,
15 when, and why the mobile in vivo radiation
16 monitoring laboratory technology was
17 developed, how it was calibrated, and the
18 operating procedures.

19 We did learn from Max Scott that
20 the techniques in calibrations of the mobile
21 in vivo lab were identical to the Y-12

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 stationary whole body counter. 12

2 We also learned who was selected
3 for chest counting and why, and information
4 regarding the reporting and interpretation of
5 the mobile in vivo results.

6 The calibration of the mobile in
7 vivo lab used a REMAB phantom. We learned
8 information about the thorium calibration
9 standard, which had a thorium-232 to thorium-
10 228 ratio of 1.27 and a thorium-232 to radium-
11 228 activity ratio of 1.67.

12 It was reported that for that
13 material the limit of detection was 6
14 milligrams of thorium. The thorium chest
15 burdens were reported in milligrams rather
16 than in nanocuries, and this was based solely
17 upon an established protocol for reporting
18 uranium at Y-12.

19 Rather than reporting activities
20 of uranium at the Y-12 counter, they also did
21 a similar reporting methodology, reporting

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 uranium mass. So to be consistent, they₁₃
2 reported thorium in mass as well.

3 Thorium-232 chest burdens derived
4 from measurements of deposited progeny are
5 basically determined by the 240 keV gamma ray
6 from lead-212, plus the 330 and 900 keV gamma
7 rays from actinium-228.

8 These photopeaks were measured and
9 allowed the mass of thorium to be determined
10 using an established Y-12 technique of using
11 ratios of the count rates from adjacent
12 regions with the interests in the spectra.

13 Some of the adjustments that need
14 to be applied to the measurements, for
15 example, when NIOSH has a measurement from the
16 mobile in vivo, we assume that the age of the
17 thorium exposure material in this historical
18 exposure scenario, we assume that that thorium
19 material age is unknown.

20 The chemical separation and the
21 purification of thorium disturbed the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 equilibrium of the thorium-232 and progeny₄
2 And so in order to bound intakes under
3 EEOICPA, we've assumed that three chemical
4 separations of the thorium material occurred
5 in order to produce the worst-case
6 disequilibrium ratio of thorium-232 to
7 thorium-228.

8 The ratio becomes, after three
9 chemical separations of the thorium over 8.8
10 years at specific times over those 8.8 years,
11 you get the largest disequilibrium ratio for
12 triple-separated thorium, which becomes a
13 ratio of thorium-232 to 228 of about 1 to
14 0.19.

15 So if you divide 1 by 0.19, that
16 gives you a correction factor of 5.25, which
17 we would apply to the measured results, but
18 you also have to correct -- I'll get back to
19 that in just a second with a specific example.

20 The next slide shows the algorithm
21 that was used by Y-12 to estimate the quantity

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 of thorium in someone's chest. And we've got¹⁵
2 an equation here which basically shows the
3 count rates in a particular region of
4 interest.

5 And, for example, the region of
6 interest from 0.208 to 0.248 is the count rate
7 from the portion of the spectrum between 208
8 keV and 248 keV, which was one of the
9 photopeaks from lead-212.

10 There's a factor representing
11 background data. It's basically from
12 measurements of 1100 unexposed workers. This
13 factor was determined to be 3.23. And then we
14 have a thorium coefficient of 8.84 to convert
15 to units of thorium mass.

16 In summary, the NIOSH and ORAU
17 whole body count experts have reviewed and
18 approved the approach to bound thorium intakes
19 and doses to workers. We believe that the
20 thorium mass reporting methodology is not an
21 SEC issue and that the thorium intakes

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 estimated from the mobile in vivo radiation₁₆
2 monitoring laboratory are plausible, claimant-
3 favorable and bounding.

4 And to get back to a brief example
5 of our proposed approach, if we have 1
6 milligram thorium chest burden of material
7 identical to the calibration source, that
8 would contain 0.086 nanocuries of lead-212.

9 So if this was actually triple-
10 separated thorium, we would then multiply this
11 value by the triple-purified thorium
12 correction factor of 5.25 to give us a value
13 of 0.45 of correction factor.

14 If you divide this by the specific
15 activity of thorium-232, 0.11 nanocuries, it
16 gives you a value of 4.1 milligrams of
17 thorium.

18 So by applying this triple-
19 separated thorium correction factor, the 1
20 milligram of thorium measured in the chest we
21 would interpret to be 4.1 milligrams. So

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 we're applying essentially a correction factor
2 of 4.1.

3 Let's see. That basically sums up
4 the approach that we have proposed to use the
5 mobile in vivo radiation monitoring laboratory
6 results to reconstruct thorium intakes.

7 The intake rates are actually
8 going to be recalculated based upon this
9 correction factor and we are working on a
10 draft of that right now at this time. And
11 with that, that's our summary of our proposed
12 approach. If there are questions --

13 CHAIRMAN CLAWSON: Hey, John,
14 before you jump in, this is Brad speaking.
15 Mark, I was kind of taken a little bit back by
16 not even knowing about this interview until
17 all of a sudden it pops up in a report that
18 you were putting out.

19 I was kind of under the
20 understanding of when we did interviews like
21 this that, you know, the other party that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 would be involved was also to be notified and¹⁸
2 then to be able to find this out coming out
3 into a report, it just kind of caught me off
4 guard with this.

5 So, you know, this person's a
6 valuable asset to be able to bring a lot of
7 this to light and I'd just want to know that -
8 - I didn't see this -- just to tell you the
9 truth, I'd probably would have wanted to be
10 involved with it if they were performing
11 interviews like this. There's a few questions
12 that I had too.

13 MR. ROLFES: Well, we did hear
14 back from Max Scott. This was, basically, a
15 last-minute schedule, based upon our tight
16 work schedule, to get results back to the
17 Advisory Board Work Group.

18 And Mr. Scott is willing to speak
19 with us again if you'd like to ask him some
20 additional questions. I'm sure we probably
21 have some clarification questions for him as

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 well.

19

2 CHAIRMAN CLAWSON: Well, you know,
3 we've tried as a Board, and we've also tried
4 as NIOSH, to be able to limit, especially to
5 these sites and these individuals, six or
6 seven different times.

7 Having to come back into this, I
8 would just appreciate that if anything like
9 this does come up, at least notify us. I
10 realize that sometimes these individuals come
11 up and it's a spur of the moment thing, but at
12 least notify us of the interview and that a
13 report is following, because I was somewhat
14 blind-sided by this report.

15 All of a sudden I had to start
16 asking, where did, you know, the interviews
17 come from and so forth like that. So I just
18 caution us to try to cooperate with each
19 other's side just a little bit better on this
20 and communicate it.

21 I know that these things come up.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 It's just I personally would like to have²⁰
2 been notified and know of it so that I knew
3 what was coming. With that, I'll turn it over
4 to John to have his response and we'll go from
5 there.

6 MR. STIVER: Okay. Thank you,
7 Brad. This is John. And thanks, Mark, for
8 the presentation. I'm going to go back to our
9 previous concerns before the Scott interview,
10 clarify some of this, and we were concerned as
11 to exactly how the milligram data were
12 derived.

13 And we know that post-1978, the
14 actual activities of lead-212 and actinium-228
15 were calculated, which then allows the
16 derivation of the age of the material, and
17 based on the lead-212 then, using Tom LaBone's
18 intake retention fraction White Paper and the
19 triple-purification claimant-favorable-type
20 assumptions, we feel that those techniques can
21 yield a plausible upper bound for that period

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 during which the activities of the progeny are ²¹
2 actually provided.

3 We never had a problem with that.

4 What we have is that we also were not quite
5 sure which nuclide was measured in order to
6 get the milligram data for the '68 to '78.
7 And the interview with Max Scott has clarified
8 that, no, they did not actually measure the
9 activity.

10 They had this empirical formula
11 here which looks at ratios. And I'd like to
12 draw everybody's attention to the paper, or
13 actually, just a technical note that we sent
14 out just a couple of days ago, April 17th. I
15 hope everybody has a copy of this.

16 It's entitled: SC&A Comments on
17 Slide 7 of the NIOSH Presentation. And before
18 I get started on that, I'd just like to take a
19 look at, in Slide 6, where Mark had discussed
20 the triple separation.

21 I think it's very important that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 we don't conflate these two methodologies. ~~We~~
2 believe this is a perfectly adequate approach
3 to take to the lead-212 measurements when
4 they're reported actually in activity units.

5 However, this particular -- that
6 would not apply to this empirical formula on
7 Slide 7. So I'd just like to kind of discuss
8 this equation a little bit and make sure
9 everybody on the Work Group, and all the
10 participants, really understand what this
11 means.

12 As Mark said, you have three
13 regions of interest. The first is for a 240
14 keV emission from lead-212. The second is for
15 the 330 keV emission from actinium-228. And
16 the third, 900 keV emission from actinium-228.

17 And what they did, these ratios,
18 really, they took the region of interest where
19 the photopeak is, they divide that by the
20 adjacent higher region, where there is no
21 counting from the particular emissions, and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 then this ration then gives you an idea ⁱⁿ₂₃
2 comparison to background, whether there is an
3 elevation in those photopeaks relative to an
4 unexposed population.

5 And I guess there's two empirical
6 values here that I'd like to discuss and this
7 really clarifies a lot to me. The first is
8 this 3.23 and the other being the conversion
9 factor to get from this dimensionless ratio to
10 milligrams of thorium, this 8.84, which is
11 contingent upon the calibration source used
12 for the calculations. That's where this 8.8
13 comes from.

14 If we take a look at the 3.23
15 first, now, this represents the ratios in
16 these three regions of interest. The summed
17 ratios for these 1100 unexposed workers from
18 the Y-12 plant.

19 And, really, this is a 3.23,
20 basically, they're just a little over 1 and
21 when you look at the spectra in the paper, I

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 believe it was the Scott paper for 1969, you
2 see there's a little bit of elevation in
3 there, but not a lot.

4 The uncertainty in that
5 distribution of summed ratios for the 1100 was
6 rather tight, as we'd expect for such a large
7 sample size, and that is 0.7. And now, I
8 understand where the 6 milligram stated
9 detection limit for the system came from.

10 It's basically 0.7 times 8.84. It
11 gives you 6 milligrams. So basically, it's
12 the uncertainty in that background
13 distribution. So if you had, essentially, no
14 differentiation between your measured
15 individual in this background distribution of
16 summed ratios, the uncertainty in that
17 empirical approach would correspond to 6
18 milligrams.

19 So it's not a detection limit in a
20 classical sense based on the accounting
21 statistics of your system using the approach

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 of Currie's paper in 1968. It's really an ²⁵
2 empirical construct.

3 And so we note that there are
4 also, if you take a look, I believe, on our
5 little paper on Page 3, we had a discussion
6 about this.

7 And so I guess the problem being
8 is that this kind of solidifies our concerns
9 regarding the detection limit and also its
10 applicability to Fernald because I note that
11 the mobile system did not have the same level
12 of shielding.

13 The iron was not quite as thick
14 and it wasn't quite as low background as the
15 thick system at Y-12. So you'd expect a
16 slightly different -- we really can't
17 determine what the difference would be in this
18 background distribution of summed ratios and
19 we would also vary depending on the number of
20 individuals who were measured.

21 I mean, obviously, if you only had

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 20 or 30, they'd have a much larger spread ^{as}₂₆
2 you get more -- you know, it's just a known
3 quantity of the central limit there and how
4 that works.

5 So anyway, that really calls into
6 question the whole issue of the 6 milligrams
7 and I know Dr. Ziemer, Paul Ziemer, had a lot
8 of questions regarding that in the last
9 meeting.

10 And that was in relation to Table
11 1, which, remember, this was this period of
12 overlap where we had two groups of workers in
13 1979, one from one plant for a short period of
14 time, another from a separate plant for a
15 short period of time.

16 And we had lead-212 measurements,
17 all but one of which were above the detection
18 limit based on that approach that we're taking
19 post-1978. And they also had another column
20 which gave, you know, milligrams of thorium.

21 And because you're looking, almost

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 certainly, at a single source for those two
2 groups, and you have a range of lead-212
3 measurements, all of which are above the
4 detection limit, you would then have expected
5 that the milligram thorium data would be
6 proportional to those lead-212 measurements,
7 if indeed, the milligram data were calculated
8 off of the lead measurements.

9 And what we found instead was that
10 every single one of those was listed as 2.1
11 milligrams. Well, the real reason for that is
12 because if you have a detection limit for
13 lead-212 of 0.23 nanocuries and you assume
14 secular equilibrium, that's going to correlate
15 just based on the specific activity for
16 thorium, it's going to be 2.09 milligrams. So
17 that's where the 2.1 came from.

18 What they did is, they just
19 assigned the MDL value of milligrams that
20 would have corresponded to the detection limit
21 for lead-212. And, you know, we brought that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 up and we keep bringing it up at every²⁸
2 meeting, practically.

3 Just illustrate that, here's the
4 situation where you have a set of data, but
5 you've got a comparison of the two. And it
6 looks like the approach that had been declined
7 by NIOSH really wasn't used. And so now, when
8 we can step back, we can also look at this
9 from another view is that, well, now we know
10 what the 6 milligrams really means.

11 And it's a highly variable
12 quantity that depends on the characteristics
13 of the summed ratios for these unexposed
14 workers.

15 The other aspect of this is this
16 value 8.84, this conversion factor to get from
17 this dimensionless ratio to milligrams of
18 thorium.

19 And looking at the papers by Mr.
20 Scott and Mr. West back in the mid-'60s where
21 they were doing this system development, it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 appears that what this really does is this is
2 another empirical value which basically takes
3 that calibration source they had at Y-12,
4 which was at about 80 percent equilibrium for
5 lead-212 and about 60 percent for radium.

6 And they used that, placed in
7 their REMAB phantom in the lung tissue, I
8 believe they used sponges to simulate lungs in
9 this phantom, and put these little vials of
10 material in there, and then they knew the mass
11 that they were inserting, and they were able
12 to determine that, you know, when you get a
13 ratio increase of 1 compared to the unexposed
14 group, this corresponds to about 8.84
15 milligrams of thorium.

16 And so they indicate that they
17 selected that source to be representative of
18 the thorium that was being handled there at Y-
19 12.

20 Well, now you take this system,
21 you got a mobile system now in a tractor

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 trailer rig, and you're moving it around to
2 the different labs, but the real reason for
3 using this was to measure U-235 and get
4 maximum permissible body burdens.

5 The thorium measurements were kind
6 of ancillary, but they had a technique and
7 they could apply it. So, you know, they're
8 here, we can measure them, let's go ahead and
9 measure thorium too, but the real reason was
10 to measure uranium and get these, you know,
11 quantitative measures of the MPBD for that.

12 But when you're taking it to place
13 like Fernald where, during a period of thorium
14 production, you have all different types of
15 sources.

16 You've got type M, you got type S,
17 you've got freshly separated material from the
18 refinery, you've got that feeding them and
19 being converted to an oxide; very similar,
20 almost exactly similar to the uranium
21 processing approach.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 Then it's fluorinated to produce₃a
2 tetrafluoride, which is then reduced to metal,
3 and so forth, and then, I believe in thorium,
4 they sent it offsite for extrusion into rods,
5 but there was some machining done there as
6 well.

7 And so you have this whole range
8 of source terms; ages of the source. And so
9 when you try to apply this value, we have a
10 set of ratios to some of them.

11 And that's all you have, really,
12 that summed ratios, and you've got this
13 calibration factor which is dependent,
14 entirely, on the characteristics of the
15 calibration source and you hope that it's
16 representative of the material you're actually
17 trying to measure.

18 And in our little ditty here, we
19 did some calculations, Joyce actually did
20 these calculations, where she took an example,
21 okay, we've got a type M thorium, the guy is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 exposed for 60 days, and then he's monitored³²
2 in the mobile laboratory.

3 We looked at several different
4 contingencies. First, we looked at the middle
5 of his exposure, 30 days from the onset of the
6 intake, we looked at the last day of
7 exposures, and then at 90, 120, 180, and 360
8 days after the first day of exposure.

9 And what we did, we kind of
10 finagled just a little bit, just for
11 illustrative purposes, we used the detection
12 limits that were in place post-1978 in units
13 of nanocuries.

14 And when we took a look at this
15 and we said, okay, let's look at three
16 different contingencies. We've got a material
17 that's essentially in equilibrium. And they
18 looked at, okay, given this 10 -- oh, and,
19 basically, what you wind up with is a 10
20 milligram value at these different time
21 periods.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 And so, you know, based on just³³
2 the range of, we presented something similar
3 to this at the meeting, but just bear with me,
4 intakes over this period of time,
5 corresponding it to 10 milligrams, it ranges
6 over about from 17 to 140 becquerels, so it
7 spans about an order of magnitude.

8 If the worker was exposed to
9 material in equilibrium, it would be
10 detectable. Then we took a look at, okay,
11 let's take this triple-distilled thorium.
12 Let's look at that.

13 And so we took a look at that,
14 give it the same amount of material that would
15 be in the lungs at the end of these exposures,
16 and in those situations, the range of activity
17 of lead-212, and of actinium, would not have
18 been detected.

19 So here's a situation where you
20 would have a 10 milligram burden which would
21 be virtually undetected given this technique,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 even if you had the conversions to get back to
2 activity, which, in this case, we don't. All
3 we have are milligram values and we don't even
4 have the ratios or the count.

5 We finally looked at, okay, here's
6 another situation. Let's look at a situation
7 where you, instead of just having a triple
8 purification, we just have one purification.
9 And in that situation, you would have
10 detectable counts in the lead-212 peak by
11 virtue of the unsupported progeny of the 228
12 thorium, which would be decaying away.

13 And the progeny build-in is
14 governed by iridium-224, which builds in at, I
15 believe, a 3.6 day half-life, so within about
16 three weeks the progeny are in equilibrium
17 with unsupported 228, but then the actinium
18 ROIs, the two actinium ROIs, would detect
19 nothing. And so this is illustrative of how
20 you could have very large intakes that would
21 be missed all together.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 And so I guess, at that point,³³
2 really, I can say that our concerns aren't
3 really alleviated. If anything, I think
4 they're more crystallized here regarding the
5 applicability of this data set without any way
6 to get back to what an activity of lead-212
7 might have been.

8 The only way I can see where you
9 could get that is if you had the count data
10 and the efficiency. And from that, you could
11 apply the LaBone method to get back to a
12 worst-case situation, you know, for triple
13 distillation.

14 But as it is now, SC&A feels that
15 this is just a really unstable foundation to
16 build a coworker model on what is going to be
17 the fundamental basis for making compensation
18 decisions for hundreds, if not over a
19 thousand, workers.

20 And that's, kind of, where we
21 stand at this point. So if the Work Group or

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 DCAS want to resolve that. And I'd also like³⁶
2 to, because we have Stu onboard, and he was,
3 you know, working at Fernald during this
4 period of time.

5 Maybe, Stu, could you tell us a
6 little bit more about this 8.84, and what do
7 these values really represent, and do you have
8 any knowledge of the system and how it was
9 used at Fernald?

10 MR. HINNEFELD: Well, this is Stu.
11 I didn't start until 1981, so I wasn't there
12 during the '68 to '78 time period, but the
13 mobile in vivo counter was being used for
14 several years after I started.

15 At the time that I was there, it
16 was, really, a uranium counter. Thorium work,
17 by the '80s, I don't recall any actual thorium
18 processing or production. There was thorium
19 in storage here and there, and there may have
20 been some over-packing of containers that were
21 corroding.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 MR. STIVER: Right. 37

2 MR. HINNEFELD: But thorium was
3 largely just kind of left alone. It was in
4 warehouses. It tended to be, for the most
5 part sort of remote from the rest of the
6 plant. That's not a 100 percent true. There
7 was some thorium stored in relatively close
8 proximity to some of the process areas.

9 So my recollection from my
10 experience at having been there was: we didn't
11 pay much attention to the thorium numbers
12 because no one was really being exposed to
13 thorium anyway.

14 I have spent quite a lot of time,
15 since I've been authorized, and also in
16 anticipation of being authorized to speak to
17 the workers about this, and trying to follow
18 the discussion here.

19 And I think it's pretty clear from
20 everybody's work that, when the mobile counter
21 was recording thorium milligram numbers, it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 did not actually arrive at activities of lead³⁸
2 212 and actinium-228 as an intermediate step
3 and go from there.

4 John described really well that
5 there was just a sum of the ratios approach.
6 And so my question has always been, well, how
7 is there a method to deconvolute a milligram
8 of thorium number into lead-212 and actinium-
9 228 numbers that would give you a reliable
10 bounding estimate, because I'm pretty clear
11 you can't really deconvolute it and an amount
12 of it gives you a precise estimate and then
13 interpreting that milligram number, but can
14 you do a bounding interpretation?

15 And so from that standpoint -- and
16 some of my thoughts here just crystallized
17 during John's presentation a minute ago.
18 There are, from the calibration source that's
19 described in either the West or the Scott
20 paper, I forget which paper describes it,
21 there is some knowledge that we have about how

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 the mobile in vivo counter interpreted ³⁹
2 thorium source with those specific activity
3 ratios; how it interpreted that into
4 milligrams of thorium.

5 And so the question then is, well,
6 if you don't have a mixture of thorium that is
7 the same as your calibration source, what are
8 the possible combinations of lead-212 and
9 actinium-228 that would be interpreted the
10 same way as, say, 1 milligram of the
11 calibration source?

12 And so having, you know, thought
13 about that, it's not a simple issue to explain
14 and the discussion that John talked about of
15 the years when we have reports that were
16 listed both ways, both with the activity of
17 lead-212 and the actinium-228 and the same
18 subject reported in milligrams of thorium,
19 that, to me, kind of becomes more troubling as
20 I think about it.

21 The issue there being that, you

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 know, if, in fact, the mobile counter⁴⁰
2 interpreted -- if you have 1 milligram of
3 thorium resulted to a source that had 0.086
4 nanocuries of lead-212 and a somewhat less
5 activity of actinium-228.

6 And if, in fact, the subject had
7 freshly separated thorium in his lungs rather
8 than the calibration source mixture, then the
9 counter would see only lead-212 and it would
10 require slightly more lead-212 than 0.086
11 milligrams because the lead-212 ratio has to
12 account for the entire sum of ratios.

13 He doesn't get any additional sum
14 from the actinium piece. And so 1 milligram
15 then, if it were strictly lead-212, should
16 translate to something, you know, not a whole
17 lot more than 0.086 nanocuries of lead-212.

18 The reason being that, the paper
19 that describes the ratios and the one
20 calibration we have that shows how much each
21 region of interest contributes, shows that, at

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 least for that example, the lead-212₄₁
2 contributed more to the excess ratio than the
3 actinium-228 at, what I believe to be, the
4 calibration source ratios.

5 So if we're counting only lead-
6 212, and we got 1 milligram, then we should
7 see some value slightly above 0.086. And then
8 when you look at the measurements from the
9 year when you have both milligrams and
10 activity, and John cited some of these, you
11 have some measurements where the lead-212, I
12 think it was in the 0.4 region, maybe higher
13 than that, maybe higher than 0.4 in some
14 cases, and the milligrams were at 2, then it
15 seems to me that, just on the face of it, the
16 2 milligram in vivo result shouldn't have been
17 much higher than about 0.2 nanocuries because,
18 you know, 0.086 and a little bit bigger than
19 that, say, 1 nanocurie for 1 milligram, so
20 then 2 milligrams would be about 2 nanocuries.

21 And so if you have 0.4 or higher

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 nanocuries of lead-212, why isn't that⁴²
2 providing a sufficient boost to that sum of
3 ratios that get a higher number than 2
4 milligrams?

5 So there is a lot of stuff here.
6 A lot of complications that SC&A has kind of
7 pointed out, and there's some really sketchy
8 available data on the actual calibration, at
9 least that I've seen, calibration data.

10 So, to me, I'm really struggling
11 with making a firm conclusion here that you
12 can deconvolute that thorium number. So
13 that's what I'm struggling with

14 MR. STIVER: Yes, I guess we've
15 kind of come to the same place in that regard.

16 MR. ROLFES: This is Mark, and I
17 know we had previously discussed a potential
18 negative bias in some of the lead-212 results.

19 I'd like to check, maybe, if Bob Morris might
20 be able to possibly comment on that if that
21 would play into this discussion here when they

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 switched over from reporting mass results ~~to~~⁴³
2 the activities of both actinium-228 and lead-
3 212.

4 I believe SC&A previously had a
5 comment that the lead-212 activities appeared
6 to have a negative bias to them. And so we
7 had proposed adjusting the reported lead-212
8 values upwards by this negative bias amount.

9 Bob, I don't know if you have any
10 comments on this.

11 MR. MORRIS: No, you said it
12 correctly.

13 MR. ROLFES: Okay.

14 MR. MORRIS: We did take note of
15 the SC&A comment, which was made, well,
16 probably a year and a half ago, pointing out
17 that there was, obviously, too many negative
18 values, too many values below, hovering around
19 0 to be statistically appropriate, and we
20 agreed with that.

21 Went through and made a process of

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 a bias adjustment to bring dose up as ~~an~~
2 additive value. So I think that that is in
3 the plan for when we revise the coworker model
4 for '78 to '88. It has no bearing on the
5 coworker model for '68 to '78.

6 MR. HINNEFELD: This is Stu. I
7 mean, you know, that's an adjustment that's
8 made when the data are reported in activity
9 and if you make that adjustment to the lead-
10 212 activity for the year when you have both,
11 well, instead of having 0.4, then you've got
12 0.6 nanocuries of lead-212, and you still have
13 the same issue.

14 Why doesn't that much lead-212
15 give a higher boost to the ratio than what
16 turns into 2 milligrams? Am I right? Am I on
17 somebody's speakerphone? I hear myself
18 echoing.

19 MR. STIVER: I'm hearing the echo
20 too, Stu. This is John.

21 MR. HINNEFELD: I mean, I can deal

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 with it. It's not very loud. 45

2 CHAIRMAN CLAWSON: This is Brad.
3 It happens to me too. Actually, I was having
4 a little bit of a hard time hearing the one
5 that just spoke before you, I believe it was
6 Bob Morris or Robert Morris, because he was
7 cutting out, but I think it's just a bad phone
8 connection.

9 MR. KATZ: This is Ted. I think
10 some people have not muted their phones and
11 that's probably contributing to this
12 background noise. Somehow it's feedback. So
13 everyone who's not speaking, please mute your
14 phones, and press *6 if you don't have a mute
15 button.

16 MR. STIVER: Okay. This is John
17 Stiver. I'd kind of like to add a little bit
18 to this. Another thing that we had commented
19 on in our previous papers is the milligram
20 thorium data also don't appear to comport with
21 biokinetic processes.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 And what this means, really, ^{is}₄₆
2 that you've got very high values reported
3 followed, not immediately, but within in a
4 period of time where you should be able to
5 predict, you know, within reason, a follow-on
6 measurement would have been done.

7 And so we've got some pretty
8 oddball situations where you've got, like,
9 over 10 milligrams followed, about two months
10 later, by 0.2 or it was 0.02. I know Bob
11 Barton could probably give you the exact
12 numbers on that.

13 So I guess the issue there is
14 that, you know, we have kind of multiple
15 snapshots of evidence here, all of which kind
16 of tend to result in us questioning the
17 veracity of this data set in terms of how it
18 was actually developed, whether it was really
19 done in a way that can be used to create a
20 coworker model.

21 It would be nice if we had the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 actual count data for these regions and you
2 could kind of pick it apart and say, okay,
3 yes, well, we got more lead counts here and so
4 it's going to mean -- and once you get that,
5 then you can kind of get back to activity and
6 then you can put some bounding assumptions on
7 it, but we're kind of adrift here.

8 We don't have that hook to get
9 back to a reasonable milligram thorium value
10 and so that's kind of where we are. We're
11 just still struggling with this and I just
12 don't see a reasonable way to put a bound on
13 numbers.

14 John, we talked about this
15 yesterday. Is there anything you'd like to
16 add? John Mauro.

17 DR. MAURO: Yes. I'm here
18 listening and yes, we did. My takeaway, and
19 to really down to the bottom, I think, not
20 withstanding some of the problems that were
21 described post-'78, you may very well have a

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 tractable situation, because you do have the ⁴⁸
2 counts from lead.

3 But everything I'm hearing
4 regarding '68 to '78 is impossible. And what
5 really brought it home to me was the fact that
6 the calibration source that was used to come
7 up with this equation, I guess we'll call that
8 Max's or Hap West's equation, it's only
9 applicable to Y-12 for that particular
10 calibration source and that particular
11 background.

12 And it works as long as that, in
13 fact, is what you were dealing with. And what
14 I walked away from with is, but wait a minute,
15 that only worked for that system at Y-12 and
16 that calibration source.

17 And now you bring this on the
18 road, which is a different shielding,
19 different background, and who knows what the
20 mix is of what people are actually
21 experiencing. It certainly is not going to be

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 the mix of radionuclides that were used for⁴⁹
2 the calibration source.

3 And I walk away from this saying,
4 you cannot reconstruct those doses. You know,
5 I just can't see a way of getting out of this.

6 Now, there may be some folks on this who
7 really have a very deep and rich understanding
8 of these problems, and there may be ways of
9 teasing things apart, and maybe making
10 bounding assumptions, but I haven't heard it,
11 or if I did hear it, I certainly did not
12 understand it.

13 So right now, you know, in trying
14 to watch this and stay close to it, I can't
15 see a way out of having a tractable dose
16 reconstruction coworker model from '68 to '78.

17 MEMBER ZIEMER: This is Ziemer,
18 could I ask a question here? Hello.

19 MR. STIVER: Certainly.

20 MEMBER ZIEMER: Oh, okay. This is
21 for Mark. Mark, when you talked to Dr. Scott,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 did he indicate, when he said that they used⁵⁰
2 the same procedures, anything about the
3 counting times used for both the Fernald and
4 the Oak Ridge cases?

5 I mean, there's been a lot of
6 focus on this 3.23 factor which is associated
7 with the background data for the Y-12 group,
8 but, you know, if I were doing this, and I've
9 done a lot of whole body counting work in the
10 past, if I had different shielding and
11 different background, I would just be
12 adjusting my counting times.

13 I could get the same basic number
14 there by adjusting counting times to get it.
15 Basically, what you're after on these kind of
16 counters is looking at a figure of merit,
17 which, basically, turns out to be sample
18 squared to background ratios.

19 And if you go from one background
20 to another, you can make that adjustment
21 through counting time, but is there any

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 indication that something like that was done?⁵¹

2 MR. ROLFES: Dr. Ziemer, this is
3 Mark, and as far as, from my recollection, I
4 believe it was a 1000-second count. This is
5 just from recollection. I'd like for someone
6 from ORAU to --

7 MEMBER ZIEMER: I mean, is that
8 what was used at both places?

9 MR. ROLFES: I'll get to that. I
10 apologize. What we do know from Max Scott, we
11 do know that, I can use another example, he
12 had actually run what was the precursor to the
13 mobile in vivo at the Weldon Spring plant to
14 determine thorium exposures for workers in
15 1966.

16 And we know that, at that time, he
17 had adjusted due to the higher background of
18 that system that he built. It wasn't the
19 mobile in vivo unit yet per se, it was
20 basically a room that he had constructed which
21 had a much higher background than the Y-12

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 mobile counter. 52

2 And so in that case, at the Weldon
3 Spring plant, instead of using the actinium-
4 228 and lead-212 photopeaks, he used a
5 thallium-208 photopeak to quantify thorium
6 exposures.

7 We do know that Max Scott was
8 actually one of the first people to come to
9 Fernald with the mobile in vivo counter that
10 we're discussing today. And we know that
11 background is somehow adjusted for in the
12 counts.

13 We do know that the background was
14 much lower at Fernald with the mobile in vivo
15 than its precursor at the Weldon Spring plant
16 because they were able to use the actinium-228
17 and lead-212 photopeaks there.

18 So we do know that he was
19 involved, and Y-12 was involved, in concerns
20 about elevated background. We know that Max
21 Scott trained the personnel at Fernald to

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 operate the mobile in vivo and was also called⁵³
2 several times, as he indicated in his
3 interview, to basically troubleshoot and come
4 up to the site, to Fernald, when there were
5 issues with elevated background.

6 He gave an example of one of the
7 times in his interview that he had come up to
8 the Fernald site due to elevated background.

9 MEMBER ZIEMER: Okay.

10 MR. ROLFES: As far as the
11 counting times, I don't know the answer off
12 the top of my head if the count times were the
13 exact same or if they were adjusted based upon
14 the background count rates.

15 That's something maybe ORAU might
16 be able to answer, but I don't know the exact
17 answer at this point.

18 MEMBER ZIEMER: Well, if you're
19 going to have a follow-up interview with Max,
20 maybe you could address that. I have more
21 concerns about the other issues that John

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 Stiver raised than that 3.23 issue because⁵⁴
2 think, in principle, you can adjust the system
3 to achieve that same level of -- it sort of
4 looks like a detection limit, but it's, I
5 think as you mentioned, 3.23 times 8.84, I
6 guess; whatever that comes out.

7 MR. STIVER: This is Stiver, if I
8 could jump in again. That 3.23, you got to
9 remember, that's not based on the counting
10 statistics of the system and it's based on the
11 sum of ratios using this same approach, just
12 taking the ratios of those three photopeaks to
13 the adjacent area, the higher energy, and
14 adding those up.

15 And also, the count time that I've
16 seen is 1200 seconds, so it's a 20-minute
17 count. I haven't seen any information on what
18 the count times were at Fernald, but, you
19 know, all the calibration information is for
20 Y-12.

21 So it's not like you're actually,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you know, taking the background distribution⁵⁵
2 of your counting system so you can count it
3 longer and get more precision in this
4 situation. It's really a --

5 MEMBER ZIEMER: Well, using the
6 same calibration source in both cases, I
7 assume.

8 MR. STIVER: Yes, it's a similar
9 construct for that particular set. So if
10 you've got the same counts, unexposed, and the
11 same ROIs, you get 1100 of these people, they
12 sum those up, they get an average value.
13 That's what that 3.23 represents.

14 MEMBER ZIEMER: Right.

15 MR. STIVER: It's the average
16 counts for 1100 unexposed people. And the
17 spread in that is 0.7, and that's, then, where
18 the 6 milligram MDA came from.

19 MEMBER ZIEMER: Yes. So you're
20 talking about the three regions of interest in
21 the background and suggesting then that if the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 background is different, the regions of
2 interest are probably different then.

3 I understand your point, yes.

4 DR. LIPSZTEIN: May I clarify
5 something? When you look at those,
6 supposedly, 3.23 is correct. And that dose is
7 the same at Fernald and at Y-12. When we
8 measured the people, the persons, it's 3.23,
9 plus or minus 0.7.

10 Now, you have those three regions.

11 In order to have the milligrams of thorium,
12 you multiply it by 8.84. This is something
13 that is only related to -- that's special for
14 us that they used at Y-12. And I made the
15 simulation of someone that really had 10
16 milligrams of thorium in his lung.

17 Suppose he had 10 milligrams in
18 his lung, and suppose that the force that they
19 were dealing at Fernald had the three
20 separation steps, so what happened is that,
21 all of these three ratios that we see in the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 equation, they will all be around the 3.23. 57

2 So the result we would have, minus
3 3.23, would be between minus 0.7 and plus 0.7,
4 or minus 6/plus 6, if you multiply it by 8.84.

5 I don't know if I'm clear, but the three
6 ratios that we see in the equation would not
7 be different from the normal people, even if
8 this person had 10 milligrams in his lung.

9 And we would get any number
10 between minus 6 and 6 if we apply the
11 equation. And in reality, he had 10
12 milligrams, so we cannot determine which error
13 was --

14 So depending on the mixture you
15 had in the lung, it's impossible to determine
16 what error, was the maximum error on this.
17 Did I make myself clear? I don't know.

18 MEMBER ZIEMER: Yes. I agree with
19 that. I think that would also happen if you
20 had the same thing at Oak Ridge, though, would
21 it not?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. LIPSZTEIN: Yes. If you had⁵⁸
2 another source, yes, exactly.

3 MEMBER ZIEMER: If the
4 calibration's different from what you're
5 counting, you're going to have that same
6 issue.

7 No, I was just raising the issue
8 of whether or not they wouldn't have adjusted
9 this knowing what the background regions of
10 interest were at Fernald versus those at Oak
11 Ridge, and using the standard calibration
12 source, if they wouldn't have been able to
13 adjust for the background part of this.

14 No, I agree with your other
15 supposition that, in actual situations, if you
16 have very different ratios in an actual
17 person, your calibration is going to not be so
18 useful.

19 So I'm a little bit like Stu in
20 raising the question, can we bound from this
21 or not? I think that's sort of the question,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 realizing that you can get very different⁵⁹
2 answers depending on what those ratios are.
3 Well, I'm more concerned about those issues
4 than I am the background issue.

5 I think that part, even as a
6 starting point, could -- but we would need to
7 talk to Max Scott to see how they did that I
8 guess.

9 DR. MAURO: Paul, this is John.
10 One of the things that crystallized my
11 thinking was reading the minutes of the
12 conversation with Max Scott and it certainly -
13 - oh, Scott Max, it certainly appeared that
14 that equation that we're looking at right now,
15 was what was used with that 8.84 and it really
16 was the 8.84 that tipped me over.

17 That is, that 8.84, embedded in
18 that is a certain ratio of, I believe it's
19 radium-228 to thorium-232, and also a certain
20 ratio, I guess, of thorium-228 to thorium-232.

21 There are certain ratios embedded

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 in that which reflect a mix of radionuclides⁶⁰
2 in the calibration source that, in effect, was
3 not even necessarily a certain age of thorium,
4 but a thorium source that even had some other
5 contaminations, if that's the right word, of,
6 I want to say, radium-228.

7 So that was a very unique source.

8 And in my mind, that was not only problematic
9 as applied here in Fernald, but it may very
10 well have been problematic as applied at Y-12
11 if they did not take into consideration that
12 the actual people that they were measuring had
13 that mix.

14 And, quite frankly, how far you
15 could be wrong. You're certainly going to get
16 a bad answer if you're, you know, counting
17 everybody on the assumption that that's the
18 mix that these people have.

19 How far wrong you could be and
20 whether you could somehow find an upper bound,
21 that was my next question, and then I realize

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 that, if this was -- 61

2 MEMBER ZIEMER: Now, John, I
3 basically was asking the same question because
4 my concern was with the 8.84, not what's
5 inside the --

6 DR. MAURO: Me too. That was my
7 first concern. I agree with you.

8 MR. STIVER: Yes. The 8.84, is
9 really, that's what allows you to get to a
10 milligram value. That's really your
11 calibration factor and it is completely
12 dependent on the characteristics of that
13 source term that was being employed.

14 DR. LIPSZTEIN: And the other
15 problem, if I may, is that if someone had
16 inhaled type S thorium in the lung, the radium
17 would leave the lung faster than thorium-232
18 and would behave more like a type M than a
19 type S.

20 So if you had a type S material,
21 you wouldn't have even a worse problem. If

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you don't have, you know, the real number, you
2 just know what the sums of the parcels minus
3 3.23. So it's very difficult to go back.

4 MEMBER ZIEMER: Well, in fact, if
5 you had type S, and some of that might account
6 for what were described earlier as kind of
7 strange biokinetics, at least if you were
8 looking at these as being insolubles.

9 MR. STIVER: Well, actually, if it
10 was type S, I think, you would probably just
11 see a continuous amount. It wouldn't be any
12 decrease to speak of in the lung.

13 DR. LIPSZTEIN: But you were
14 seeing lead and actinium on both sums, and so
15 if the radium leaves, so you see the daughters
16 leaving too, so when you are measuring, this
17 will also, depending on the time after
18 inhaling that you are measuring the person.

19 MR. HINNEFELD: This is Stu
20 Hinnefeld. I don't really want to get into
21 this issue very much. I don't know that it

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 matters that much, but with respect to the ⁶³
2 differential dissolution in the lung, there
3 has to be, for type S thorium, there has to be
4 some sort of particle size consideration here,
5 because only the radium that is available to
6 the lung fluid would have any different
7 ability to depart.

8 In other words, some portion of
9 that radium would be within the particle and
10 not available to be treated differently than
11 the thorium particle itself. I mean, I don't
12 know if we need to get into that very far
13 because I don't know that that's a very big
14 issue.

15 MR. STIVER: That is true, Stu.
16 You're right.

17 CHAIRMAN CLAWSON: This is Brad
18 speaking. You know, we get into a lot of this
19 stuff all the time. Basically, there is so
20 many uncertainties out there. I'm of the
21 opinion, we've discussed this for how many

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 months now, that, you know, it'd really be
2 hard to be able to come to a concluding point
3 on this.

4 And, Paul, this is where it
5 basically comes down to; as the Work Group,
6 we need to make the decision on this. We can
7 debate this, go back and forth, and we can
8 make a real nice science project out of it,
9 but the bottom line is, that isn't what I feel
10 that we're here to try to do.

11 I think we've given it a good
12 faith effort and, myself, I think that it just
13 ought to come before the Board at the next
14 Board Meeting and be presented this way.

15 I don't know about your feelings,
16 Paul. I guess this is what I'm asking you.

17 MEMBER ZIEMER: What I haven't
18 heard -- you know, we just saw this stuff in
19 the last day, but what we haven't heard, I
20 guess, is whether or not, given the wide range
21 of potential doses, I mean, it has been

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealgross.com

1 illustrated, depending on those ratios, does
2 that mean you can't bound?

3 That's N/A, are you saying that
4 you can't plausibly bound? I mean, you've
5 indicated that --

6 MR. STIVER: That's our position,
7 that you just can't put a plausible bound on
8 these numbers because of the fact that there
9 could be such a huge variability that you
10 can't possibly quantify.

11 DR. MAURO: And Joyce made a very
12 good point just now that, I was listening to
13 it and she said that, you could actually have
14 a person that you would say is below -- you'd
15 go through this process, you would say he's
16 below the lower limits of detection, and
17 thereby assign one half the 6 milligram, when
18 in fact, he could have had 10 milligrams.

19 MR. STIVER: Or typically a lot
20 more than 10.

21 DR. MAURO: Or more.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER ZIEMER: How much more? 66

2 DR. MAURO: Yes. I can't say.

3 MEMBER ZIEMER: Well, that's sort
4 of what I'm asking. What could it be and you
5 could still miss it? I mean, is that a way of
6 bounding? See what I'm saying?

7 MR. HINNEFELD: This is Stu
8 Hinnefeld. I just want to comment on that.
9 Recall, though, that our bounding approach
10 calls for essentially a factor of five
11 multiplier, on the indicated activity, based
12 on lead-212 if you know what the lead-212.

13 So, in fact, if the person had, I
14 haven't done all the math on this, but 10
15 milligrams of thorium and being missed. In
16 fact, if we were going to do that factor of
17 five multiplier, it would seem to me, then,
18 that the missed dose would not rely upon the 6
19 milligram number or half of that, it would
20 rely on five times that factor. If that was
21 really during the day. So taking into

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 account, I mean, the fact that we said, well⁶⁷
2 we'll interpret these data as a triple
3 separation of this worst case. Joyce has
4 started from 10 milligrams and shown where you
5 can't see that, but I don't think we would
6 claim we would. If you say that's 6
7 milligrams, then it would become 30.

8 We're talking about issues here
9 that I don't think are the key issues, because
10 the key issue is that lead-212 number.

11 MR. STIVER: Yes. If you don't
12 have a lead-212 number, you're adrift. You
13 have no way to get back to the true value.

14 DR. MAURO: Stu, I think our
15 position is that post-'78, when you have the
16 lead-212, and I think that this adjustment
17 factor that you're referring to, and certainly
18 correct me if I'm wrong, that all applies to
19 the post-'78 lead-212 data that's available to
20 us.

21 But when you go to the '68 to '78,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 correct me if I'm wrong but that's not at
2 play; these adjustment factors, et cetera, or
3 what we have in this equation, and the
4 inherent flaws in the equation, especially
5 regarding the calibration factor that gives
6 you that 8.8, whatever the number is.

7 See, that's the rock that equation
8 stands on and I don't think that rock is
9 necessarily very good and the effects of that
10 being wrong are not applicable to a given
11 worker at Fernald. I guess the question
12 becomes: how wrong could you be?

13 And I don't think we've addressed
14 that.

15 MR. HINNEFELD: Well, actually,
16 and that's the part of your guy's argument
17 that I really can't refute. That's what I
18 tried to say a while ago in different --

19 DR. MAURO: And, Joyce, you looked
20 at this pretty carefully. I mean, is there a
21 way, you know, that someone could say, well,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealgross.com

1 let's assume this, this, and this, it could
2 never be, under any circumstances, higher than
3 some number?

4 Of course, when you start going
5 that road, you're inventing a set of
6 conditions that may or may not have ever
7 existed, but, you know, everything I've heard
8 is that, you know, it could be a hundred times
9 higher.

10 Let's go to this triple-separation
11 process that you folks make reference to. My
12 understanding, under those circumstances, if
13 you are counting a person relatively shortly
14 after that process and he had a very large
15 intake, you would not see anything, but he
16 could have an extremely high body burden of
17 thorium.

18 Now, I haven't heard what those
19 numbers are, but that's a scenario that is not
20 out of the question. Do we have a feel for
21 how high? I mean, that would be a worst

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 circumstance, I presume, that is triple⁷⁰
2 separated, which means you have minimal amount

3 --

4 DR. LIPSZTEIN: Hello?

5 DR. MAURO: Yes, Joyce?

6 DR. LIPSZTEIN: Yes. Okay. Let
7 me --

8 DR. MAURO: How bad could it get?

9 DR. LIPSZTEIN: Yes. That's the
10 example that I did, was to take the
11 separation. We accepted that this factor of
12 five is valid when you have the lead-212
13 measurement result. But when you have the
14 milligrams, I did exactly this example because
15 then you -- even if the person has 10
16 milligrams in his lung, the results of
17 applying this equation would be any place
18 between minus 6 and 6, or even, I don't know,
19 even this 0.7 that makes it go from minus 6 to
20 6.

21 I don't even know if this is 95

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 percent of the mean, 99 percent of the mean,⁷¹
2 68 percent of the mean. I don't know. There
3 is nothing about this 0.7 error, but it's
4 3.23, plus or minus 0.7.

5 So when you have your result and
6 take out 3.23, minus or plus 0.7, and multiply
7 by 8.8 something, you get between minus 6 and
8 6 with a mean of 0. That's what you would
9 have for a person that would have 10
10 milligrams.

11 But maybe it can even go below
12 that, because I don't even know if this 0.7 is
13 95 percent of the distribution, if it is 68
14 percent of the distribution, if it is one
15 standard deviation, two standard deviations,
16 three standard deviations, we don't even have
17 this information.

18 So, you know, you can get from
19 negative numbers to positive numbers because
20 you are subtracting, you know, something that
21 you don't see. It's similar to someone that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 is not exposed. And in reality, he had ~~10~~⁷²
2 milligrams.

3 So you can't apply this five times
4 correction factor when you know the lead-212
5 result. It doesn't apply here.

6 MR. HINNEFELD: Yes, Joyce. This
7 is Stu Hinnefeld. I'm not arguing your point
8 at all. Just a clarification, in the, I
9 guess, West paper from '65. It's the paper
10 from 1965. I think it's the West paper. Oh,
11 I'm sorry. It's by Scott in 1965, sorry,
12 1966, where he gives the tables of the ratios
13 plus or minus 0.67 in the paper, it's
14 described as 95 percent confidence interval.
15 So that'd be the two-sided 95 percent
16 confidence interval on that.

17 DR. LIPSZTEIN: Okay.

18 MR. STIVER: Yes. It's the Table
19 1 on Page 102. That's right.

20 MR. HINNEFELD: I'm not arguing
21 your point. I just wanted to point that out

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 to you.

73

2 DR. LIPSZTEIN: Okay.

3 DR. MAURO: I think that's a
4 question that has been bothering me. Like, in
5 that equation, with the 8.84, I think that was
6 the number, the calibration factor. So there
7 was a source that they put in a phantom that
8 had a certain mix of radionuclides that
9 basically said, you know, that was to have
10 this source.

11 Now, let's say the source that was
12 put in the calibration was freshly separated
13 thorium without, basically, effectively, any
14 progeny there, except the thorium was 232 and
15 the thorium-228, that would be it. There'd be
16 nothing else there for all intents and
17 purposes.

18 And you put that in your phantom
19 and it was a large source, you know, some
20 large source, would you see anything in your
21 regions of interest? Would it come back as

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 if, no, this guy's at background, and let's
2 say it was a very large source that was put in
3 there.

4 In other words, it'd be silly, of
5 course, to do that. I'm not saying anyone has
6 done that or should do that, but what I'm
7 saying is: would you see anything in your
8 regions of interest above controls,
9 background?

10 MR. HINNEFELD: John, this is Stu.

11 It depends on how quickly you count it after
12 you separate it. What will go back in first
13 is, it will look like the lead-212 number.
14 It's actually one of the precursors to lead-
15 212, which is below thorium-228, and has about
16 a three-day half-life.

17 And so that three-day half-life
18 in-growth of the rest of the chain, then
19 through the lead-212. So that's what you
20 would count. If you count it the day after
21 you got the separation, you probably wouldn't

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 see anything, and then the lead-212 would
2 appear to grow in with, I think it's about a
3 three-day half-life.

4 DR. MAURO: Okay. So within a
5 relatively short period of time, you start to
6 see a delta between your regions of interest
7 because you start to get this in-growth that
8 would be detectable.

9 So even if you did calibrate with
10 some fresh source, you know, certainly not the
11 minute it came out, but within a week or so,
12 you know, there would be some in-growth.

13 See, what I'm trying to do is
14 really help see if we could find a way to come
15 out an upper bound, because we do know that
16 people at Fernald could very well, some of
17 them anyway, been exposed to fairly freshly
18 separated material with a minimal in-growth of
19 progeny. That's probably the exception.

20 Most of it may, especially, you
21 know, have been of some age and I guess I

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 really haven't heard an explanation, to me⁷⁸
2 that I understood that said, you know, reality
3 is, you could have a guy go in and be counted
4 under this technique, and it's between '68 and
5 '78, come back and say: we don't see anything.

6 Okay. We don't see anything.
7 And, in fact, he could, in fact, have had as
8 much as this. And I don't think it's 6
9 milligrams. That's my problem. In other
10 words, you know, the 6 milligrams seems to me
11 the one that works for that calibration
12 source.

13 But, you know, in other words,
14 when I say the calibration, if the person had
15 that mix in him, then you would say, my MDL is
16 6. But if, in fact, what the guy actually has
17 in him is something that's relatively fresh
18 and a lot different than the calibration
19 source, how bad can it get?

20 And I think that's what we're all
21 looking for. Is there a way to say, well --

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 MEMBER ZIEMER: Well, that's the
2 same question, John. That's the same question
3 I'm asking. What's the worst case that you
4 could miss?

5 DR. MAURO: Yes, right.

6 MEMBER ZIEMER: Or is there a
7 plausible bounding based on this sort of great
8 uncertainty? I guess NIOSH is still saying
9 there is? Is that right, Mark or Stu? And
10 SC&A is saying there isn't?

11 DR. MAURO: That's where it comes
12 down to. I agree with you, Paul. We're
13 fishing away to find that number.

14 MR. STIVER: Well, I guess, you
15 know, depending on how early you're willing to
16 go. I mean, if you were within a day or two,
17 you would see nothing. If you waited three or
18 four days you'd get one half-life of radium-
19 226 and the short-lived progeny build-in.

20 You'd start to see a little bit of
21 a bump on the lead-212 peak.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER ZIEMER: I guess you're
2 saying, if it's nothing, then you can't bound
3 it.

4 MR. STIVER: That's just it. So
5 you have, in the extreme case, you have a guy
6 working with freshly separated thorium in the
7 refinery area, gets a snoot full of it, they
8 happen to count him a couple of days later,
9 very unlikely situation, but it could happen,
10 and he might have gotten 50 milligrams and
11 you're going to see nothing.

12 And then you've got a whole
13 continuum up to the equilibrium situation that
14 --

15 MEMBER ZIEMER: Well, a couple
16 days later, I think there is, theoretically, a
17 number in the region of interest and it may be
18 lost in noise, but that's sort of the
19 question: how big would that have to be before
20 you could miss it?

21 MR. ROLFES: This is Mark Rolfes,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and this is something that we've considered,⁷⁹
2 And we've agreed because if this exposure
3 condition occurred, basically, someone working
4 with thorium and then getting a chest count
5 following that immediately, if they would only
6 have one chest count, this would be an issue.

7 However, if they had a second one
8 following that, it would be less of an issue.

9 Anyway, to address this concern, we've
10 proposed defaulting to the 50th percentile
11 coworker intake rate for all employees;
12 essentially.

13 So rather than use the
14 individual's own exposure data as his own
15 data, we've proposed that, collectively, the
16 entire collection of data would be used for
17 any individual potentially close to thorium.

18 MR. STIVER: But that's your
19 basic, you know, missed dose model, but that
20 really doesn't answer the question of what
21 would be a plausible upper bound.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 DR. MAURO: And, John, let me also
2 weigh in, but that presumes the database upon
3 which you generate your 50 percent is sound.
4 We're saying it isn't. You see the circular
5 argument? You can't use --

6 MR. HINNEFELD: John, this is Stu
7 and I think I would differ with that.

8 DR. MAURO: Go ahead.

9 MR. HINNEFELD: In order for this
10 to be a critical problem with the entire
11 population of results, then all the results
12 would have to be taken within a day or two of
13 the thorium separation. Seems kind of
14 incredible.

15 If you have, on occasion, that
16 happens to a person, on occasion, then you
17 would have an issue with that person's in vivo
18 count, and so don't give less than this amount
19 to a monitored person.

20 But in order for the database to
21 be really sullied, so to speak, by that issue

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 of accounting immediately after separation,⁸¹
2 you would have to have a pretty good chunk of
3 the data counted in that fashion.

4 And, you know, it just seems to be
5 too much coincidence, because remember, the
6 mobile counter was there for campaigns, maybe
7 once or twice a year, and they'd run as many
8 people through as they could.

9 So to think that you were going to
10 consistently count everybody within a couple
11 days of a thorium separation just doesn't seem
12 credible to me.

13 DR. MAURO: Yes. No, I understand
14 what you're saying.

15 MR. ROLFES: Stu, this is Mark
16 once again. And this fact was documented,
17 actually, the concern about the in-growth of
18 progeny. This is documented prior to the
19 arrival of the mobile in vivo radiation
20 measurement laboratory at Fernald.

21 It was documented in either the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Hap West article or in the Scott paper, either⁸²
2 in 1965 or 1966, so they did consider this
3 before they began counting Fernald workers.

4 MR. STIVER: I think they
5 understood the problem at the time, yes. It
6 could be a problem.

7 DR. LIPSZTEIN: May I go back to
8 the equation again, because even if the lead-
9 212 was spilling and you could see something
10 above that bound on the lead-212, you still
11 have to two actinium fix that would be similar
12 to the two actinium fix in the normal
13 population, the non-exposed population, which
14 is embed on this 3.23 here that you are
15 subtracting.

16 So I don't know if, when you don't
17 have the two parts of the two actinium fix
18 being summed, and subtracting by 3.23, and
19 multiplying by 8.84, if you really get what it
20 was in milligrams in the lung of the person,
21 you know, because they did this when they had

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealgross.com

1 this equation, this value, when they have the ⁸³
2 three picks, the two from actinium and the one
3 from lead.

4 MR. STIVER: I guess the question
5 becomes, how distorted can this be and the
6 worst-case situation, does that still yield a
7 credible, or plausible, upper bound? That's
8 kind of what we're struggling with at this
9 point.

10 DR. MAURO: This is certainly the
11 toughest brainteaser we've ever had. It's got
12 to be. I have to tell you guys, to try to
13 tease this apart and come to something that is
14 understandable, with a clear path for setting
15 an upper bound, you know, I have to say, I am
16 struggling to try to find a way.

17 And I try hard to find a way,
18 believe me, and this one has got me, anyways.

19 It's beyond my ability to really tease out
20 and say, well, if you do this, this, and this,
21 and I'm always looking for that, you know, you

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 could find an upper bound, whether it's
2 plausible, of course, that becomes your next
3 question.

4 Well, I haven't even gotten to
5 that place where I could say, I think you
6 could place an upper bound because this
7 equation doesn't apply to Fernald, or
8 necessarily apply to Fernald. It's sort of
9 like this construct that only applies to a
10 very specific circumstance.

11 How do you take something like
12 that and say, well, we could play with it and
13 find a way to apply it to the worst-case
14 condition that might have occurred at Fernald?

15 I just can't imagine what you can do.

16 MR. HINNEFELD: I think, in my
17 mind, it's talking about what's the worst-case
18 condition, probably the question has to be
19 that, you know, what (Phone interference) tell
20 us? What milligram number would it spit out?

21 (Phone interference) worst case, or most

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 favorable to the claimant. 85

2 (Phone interference) mixture --

3 MR. STIVER: Hey, Stu, you're kind
4 of breaking up. I can't hear you. This is
5 Stiver.

6 MR. HINNEFELD: I'm sorry. I'll
7 try and get --

8 MR. STIVER: I don't know if
9 anybody else is having that problem.

10 MR. HINNEFELD: If we say, okay,
11 here is a worst-case mixture and maybe it's
12 triple freshly separated and then all you have
13 is the lead-212, you know, we're going to give
14 it a few weeks or so to grow in. All you have
15 is the lead-212 and maybe that's the highest
16 dose intake, I don't know that, of the
17 possible mixtures of stuff.

18 And then, you know, we kind of
19 know what the intake would be in that
20 situation, but do we know what the in vivo
21 monitor would tell us? If we had X amount of

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 lead-212, do we know what the in vivo counter⁸⁶
2 would tell us in terms of milligrams of
3 thorium? To me, that's the question.

4 MR. STIVER: And that's where I
5 get back to the proportionality issue that we
6 were talking about earlier.

7 MR. HINNEFELD: Yes. I mean, what
8 we've got now is, we've got a data point where
9 if there's no thorium it'll tell you it's 0 if
10 it's right on the -- or some distribution
11 around 0. And if the ratio value for the
12 specific mixture in the calibration source, if
13 it's 1, then it's a little less than 9
14 milligrams.

15 But if we only have lead-212, if
16 that is the highest dose intake, and we don't
17 have the additional contribution of the
18 actinium, do we know what the in vivo monitor
19 would tell us?

20 And then, we have a data set to
21 compare whether, in fact, it seems to tell us

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that, at least we could -- and this is where⁸I
2 get back to the couple years where we had the
3 paired measurements, both actinium and the
4 math.

5 If, in fact, we believe that it
6 takes so much, like, lead-212 to give us 1
7 milligram of thorium readout in the mobile
8 counter, and that would be in the absence of
9 any actinium.

10 And then we have these
11 measurements that have actinium and lead-212
12 both, and an associated milligram number, then
13 the milligram number in every case should be
14 higher than what we believe the counter would
15 tell us if it only had the amount of lead-212
16 reported with that milligram number.

17 It's very hard to say in a
18 comprehensible fashion, but there's a way to
19 test whether the mobile counter gives results
20 that we think it should give in a way. You
21 can't test it completely, but you can prove

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 yourself wrong, you can't prove yourself⁸⁸
2 right.

3 DR. GLOVER: So, Stu, this is Sam
4 and I have done live in vivo. This is,
5 perhaps, a modelable situation. The
6 difficulty would be in determining background,
7 efficiency, and how the counts in these
8 different scenarios can be bottled in the
9 human.

10 I mean, folks like John Hunt down
11 at Brazil and Kramer, there's lots of human
12 models you can put in the detectors. It has
13 not been done to date, though, and it is not
14 without some complexity.

15 MR. HINNEFELD: Yes. I don't
16 know, Sam. You know, you're making a science
17 project out of it. I'm not sure the answer --

18 DR. GLOVER: And I'm saying, the
19 background may be an object that I couldn't
20 overcome.

21 MR. HINNEFELD: And I'm not sure

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that answers the question. You know, to me,
2 I'm more concerned with what we know about
3 what the counter actually tells us than doing
4 a Monte Carlo calibration; something like
5 that.

6 DR. GLOVER: By doing that, you're
7 kind of implicitly accepting that the data are
8 really not adequate.

9 MR. HINNEFELD: Well, my position
10 here is that it's not really straightforward
11 how you deconvolute that thorium-232, or it's
12 that thorium mass number.

13 How you interpret that into a
14 lead-212 activity and have that interpretation
15 being consistent with the performance of the
16 counter that we observe when we have both the
17 activity measurement and the mass measurement,
18 and how do you interpret that to a lead-212 in
19 order to even start to apply all the bounding
20 factors that we apply?

21 That's what I've struggled with

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 from the start, since I've been getting into
2 this is, is how do I do that? So that's kind
3 of where I'm at. And I think anything going
4 forward, if there is more work to be done
5 going forward, and I think it should be on
6 that issue.

7 I can have a meeting with the team
8 here, the ORAU and DCAS team working on this.

9 I may refer to some tables and stuff, and
10 explain how this is going to happen, but
11 that's what I'm struggling with.

12 I believe that, yes, we have a
13 bounding approach when we have the lead-212
14 number. What I'm having trouble with is, how
15 do I know what the lead-212 number is?

16 DR. GLOVER: Yes. How do you get
17 from the milligram number based on the ratio
18 method back to a plausible lead-212 number.

19 MR. HINNEFELD: Right. A bounding
20 lead-212 number would be, you know,
21 theoretically sufficient.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 DR. GLOVER: Yes. What's the ⁹¹
2 worst it could have been given this counting
3 system?

4 MR. HINNEFELD: And then you check
5 and see, does the counter behave in accordance
6 with that.

7 MEMBER ZIEMER: This is Ziemer,
8 could you remind me again, is it being
9 proposed that this be used as part of a
10 coworker model or for individual dose
11 reconstructions?

12 MR. HINNEFELD: Well, for people
13 who have data and their data is above what the
14 -- there will be a coworker model, but for
15 people who have, actually, in vivo data and if
16 their data indicates they would get an intake
17 above what the coworker model would indicate,
18 then they would get an intake based on their
19 own data.

20 MEMBER ZIEMER: All right, but --

21 MR. HINNEFELD: People who have

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 data that's below what the coworker model ~~is~~^{is}
2 based on will get the coworker model.

3 MEMBER ZIEMER: In this case, for
4 individuals who have data, this algorithm is
5 what's being proposed and what's being pointed
6 out is that it could, because of the ratios,
7 miss a lot; possibly.

8 MR. HINNEFELD: Yes, it could miss
9 a lot, but it could -- it's not clear to me
10 there's even a way to get there, you know,
11 knowing what we would miss or not.

12 MEMBER ZIEMER: Well, I guess
13 that's sort of the question, isn't it?

14 MR. HINNEFELD: Yes. We could
15 even get from the milligrams to the lead-212.
16 That's easy.

17 MEMBER ZIEMER: Yes, right.

18 DR. GLOVER: This is the question
19 we've been debating, now, for a year.

20 MEMBER ZIEMER: Right. And then
21 if you can't do that, then it means you can't

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 bound the dose for every worker. 93

2 MR. HINNEFELD: That would seem
3 that way to me.

4 DR. MAURO: And, Stu, let's say
5 you have a worker where it's reported as 10,
6 12, whatever, 18, milligrams. It's reported,
7 but it's reported based on this equation.

8 And if this equation didn't really
9 apply to his mix, you know, his background,
10 and the mix that he had in his body was not
11 the one for which this equation was developed,
12 you know, with the calibration, there's even
13 some question whether or not you can use that
14 reported milligram number for that worker.

15 I'm not sure, you know, whether or
16 not that worker could very well have been
17 higher or lower than what was reported for him
18 because of the problems inherent with using
19 this equation to derive that number.

20 MR. HINNEFELD: That's kind of
21 what I'm coming at here, is there a way that,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you know -- I think that's part of what I'm
2 saying here too is that --

3 MR. STIVER: Well, you need to get
4 out of the context of the coworker model all
5 together, it'd be just for individual dose
6 reconstruction? And is that number even --

7 MR. HINNEFELD: I mean, that
8 thorium milligram number is true only for a
9 mixture that is the same as the calibration
10 source.

11 So the question is, do we know
12 enough about how the calibrational source
13 contributes to the ratio in the three regions
14 of interest so that how much contribution do
15 you get from lead-212? How much contribution
16 to the excess ratio do you get from actinium
17 first and actinium second?

18 What are the relatives and then,
19 do we know enough to know that? And if we
20 know enough to know that, then we might be
21 able to surmise, you know, what different

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 combinations of actinium and lead-212 would⁹⁵
2 contribute to the ratios.

3 And so at that point, then you
4 would be able to come up with some alternative
5 to that 8.8 whatever number in terms of
6 interpreting, and maybe you wouldn't -- you
7 know, we're kind of going backwards. You
8 know, that 8.84 doesn't mean, really, 8.84
9 milligrams of thorium, because we don't have
10 the same mixture, but because with this other
11 bounding mixture, the in vivo counter would
12 tell you it was 8.84 when it really was this
13 other mixture of lead-212 and actinium.

14 And based on that, and some
15 conservative assumptions, then a high end -- I
16 don't know if we can do it or not. I'm
17 telling you that.

18 MR. STIVER: How many
19 confirmations of those three ROIs could give
20 you a ratio of 1; essentially? Yes. So
21 there's so many unknowns in this and I'm

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 know, how would it react to that, and what
2 number do we get out, I don't know that we can
3 do this or not.

4 But if there's anything else to
5 do, it would be along those lines; I think.

6 MEMBER ZIEMER: Could I ask one
7 other clarification? The denominators of the
8 region of interest, are those all the valleys,
9 which would be taken as background numbers?

10 MR. STIVER: No. Those are the
11 adjacent --

12 MEMBER ZIEMER: Adjacent valleys,
13 right?

14 MR. HINNEFELD: It's the higher
15 energy adjacent region on the interest and
16 it's --

17 MR. STIVER: Yes, so it's the
18 adjacent higher energy region.

19 MR. HINNEFELD: Yes.

20 (Simultaneous speaking.)

21 MEMBER ZIEMER: If you put a

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 source in, it's the valley, right? 98

2 MR. HINNEFELD: Yes. It would be
3 the valley to the high energy side.

4 MR. STIVER: Yes. It works out
5 that way, yes.

6 MEMBER ZIEMER: Right. So the
7 enumerator numbers out of the peak energy
8 ranges and does anybody look at the ratios of
9 those, because that tells you something about
10 the mix?

11 MR. HINNEFELD: Well, if we have
12 them.

13 MEMBER ZIEMER: Yes. That's what
14 I'm asking.

15 MR. STIVER: All we have is the
16 milligram number. If you have the counts, you
17 could work your way back.

18 MEMBER ZIEMER: Yes. You've got
19 the end result of what was plugged into this,
20 in principle, the regions of interest tell you
21 something about the mix.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MR. STIVER: Yes. That's all
2 you've got. And I think that's kind of where
3 Sam was going if I can be so bold as to --

4 DR. MAURO: Absolutely, yes. If
5 you knew that.

6 MR. STIVER: You would try to
7 follow the model of the detectors.

8 MEMBER ZIEMER: No. I'm asking if
9 that's part of the raw data set.

10 MR. STIVER: Unfortunately, there
11 is no raw data set for this.

12 MEMBER ZIEMER: All we have is the
13 output.

14 MR. STIVER: Milligram number.

15 MEMBER ZIEMER: Yes. Got you.
16 Okay.

17 MR. ROLFES: This is Mark. There
18 is some limited raw data, but for the majority
19 of the cases, we do not have the mobile in
20 vivo printout showing the number of counts
21 under each region.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MEMBER ZIEMER: Each region¹⁰⁰
2 because that would, sort of, answer the
3 question pretty fast.

4 DR. MAURO: Yes.

5 MR. STIVER: Yes. If we had that,
6 that would be our --

7 DR. MAURO: We'd be done.

8 MEMBER ZIEMER: So what we're
9 really talking about is, what's the worst-case
10 ratios? If there's something to be bounded,
11 it would have to be, sort of, what Stu
12 described there.

13 But I'm wondering, I know that
14 we'd like to come to closure on this, if the
15 NIOSH team would want to take a look at
16 whether they think something like Stu
17 described is feasible or not?

18 Can you actually get plausible
19 bounding for these individual cases where
20 you're going to reconstruct dose from a
21 person's count?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 MR. STIVER: Given just the
2 milligram value.

3 MEMBER ZIEMER: Yes. What's the
4 worst it could be or can you not do it?

5 MR. HINNEFELD: Yes. I think we
6 would owe that. I think if there's going to
7 be further discussion, that's what we would
8 have to provide not just to the Work Group,
9 but if the Work Group wants to, the whole
10 Board for further discussion when it's
11 available.

12 That's not going to be something
13 that can be done in a day or two, I don't
14 think.

15 CHAIRMAN CLAWSON: This is Brad.
16 I just wanted to throw out something too, and
17 this is called timeliness. We've been playing
18 with Fernald for how many years now? I think
19 that we need to also put in something to
20 prospective new -- but we owe the petitioners
21 something.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Gentlemen, I think that, if given¹⁰²
2 enough time, we could battle through all of
3 this stuff, but I want us to all remember that
4 this is a compensation program and we owe it
5 to the petitioners.

6 If we haven't got it by now, I
7 really think that we have an obligation to be
8 able to bring it before the Board and make
9 this decision. We're talking this ten-year
10 time frame here. We've been battling this for
11 a very, very long time.

12 And my personal opinion is, in my
13 opinion, this is just mine, time's up. You
14 know, we can battle this and we can go on for
15 years, but that isn't what we're here for.
16 And we're all looking at this and I understand
17 we all want the best, but the bottom-line is
18 what it comes down to is, NIOSH feels that
19 they can, SC&A feels that they can't.

20 I guess, in my opinion, that this
21 ought to be brought before the Board. I've

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 been trying to bring this before the Board for
2 the last two to three meetings. To me,
3 personally, I'll just put it blunt; time's up.

4 Let's proceed forward.

5 So with that, Paul, I understand
6 you have something to say.

7 MEMBER ZIEMER: I'm certainly in
8 favor of timeliness. I don't think that the
9 Board doesn't actually have specific
10 guidelines on that. We are charged with
11 looking at whether there's a scientifically
12 appropriate way to do these things.

13 I guess I'm certainly, Brad,
14 willing that we propose to the Board. If
15 NIOSH is not able to resolve this by the time
16 of the Board Meeting, or, you know -- I think
17 we've got several weeks here. Let's see, what
18 do you we got time-wise?

19 MR. HINNEFELD: Well, if you're
20 talking about the in-person Board Meeting,
21 that's in --

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 MR. STIVER: June 19th, isn't it?¹⁰⁴

2 CHAIRMAN CLAWSON: This is Brad.
3 We have scheduled, on the 26th, to discuss
4 Fernald for this time period. And this came
5 from the full Board meeting last time.
6 Basically, the following before that. Go
7 ahead.

8 MR. KATZ: This is Ted. Yes. So
9 it's on the Board Meeting schedule for next
10 week and, yes, I think the sentiment at the
11 last Board Meeting was that it would be
12 possible to take action on the teleconference,
13 not that it's a forgone conclusion.

14 But the full Board wanted the Work
15 Group to flesh out its last materials. The
16 full Board also wanted the Work Group to have
17 an opportunity to engage DCAS on the question
18 of, if there were to be a determination of
19 non-feasibility for this period, whether there
20 were any Class Definition issues that need to
21 get sorted out in advance.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 You know, not prejudging the
2 Board's final decision on that matter, but to
3 prepare for that possibility.

4 MR. HINNEFELD: Yes, Ted, with
5 respect to that issue, we have thought about
6 what's available and we don't believe there is
7 a Class Definition that's suitable, other than
8 all workers.

9 MR. KATZ: Okay. So that settles
10 that question. That's great.

11 MEMBER ZIEMER: Could you close my
12 door.

13 MR. KATZ: What?

14 CHAIRMAN CLAWSON: Somebody's door
15 is needing closed. So basically, to me, we're
16 at a point where we're going to bring this
17 before the Board next week. NIOSH and SC&A
18 can present to the Board. My feeling, Paul,
19 is that we bring this before the Board on the
20 teleconference.

21 MEMBER ZIEMER: Oh, yes, okay.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 The Board already decided they wanted to do
2 that and that's what we do, yes.

3 CHAIRMAN CLAWSON: Right. I
4 understand that. So not wanting to cut
5 anybody off on this rousing discussion that we
6 have here, I think that we need to move on.
7 Is there anything else that we need?

8 We've got the in vivo bioassay
9 White Paper, the SC&A response, have you
10 discussed that thoroughly, John?

11 MR. STIVER: Excuse me?

12 CHAIRMAN CLAWSON: I see on Ted's
13 thing we've got an SC&A response to the in
14 vivo thorium bioassay method. I think that's
15 what we've been discussing.

16 MR. STIVER: That's what we've
17 been talking about today, yes.

18 CHAIRMAN CLAWSON: Right. That's
19 two of them right there and DCAS has performed
20 theirs. You know, this bottom-line, to me,
21 this is what we've been talking all day and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 the only thing I see on the agenda is this¹⁰⁷
2 part of it right now.

3 Paul, you know, you can weigh in,
4 I don't know why we don't have all the Board
5 Members here, and so forth, but I thought
6 we've already discussed this and we'll just
7 bring this before the Board on the 26th.

8 MEMBER ZIEMER: And that's fine,
9 you know? See, I detect some uncertainty with
10 NIOSH at the moment in terms of their
11 position, but it may be that they'll have some
12 additional information. It's not very far
13 off, but if they have additional comments,
14 that would be helpful.

15 I mean, I'm not confident at this
16 point that we have a plausible upper bound, so
17 if we were to vote today, I would have to
18 favor going with a Class, but, you know, it
19 seems that, in principle, one should be able
20 to discover, in terms of some number that,
21 once you pass that number, you could detect

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 it, number one, in the in vivo counter. 108

2 And that number would then be your
3 upper bound, but we haven't reached that
4 point. So here we are.

5 MR. KATZ: So this is Ted. Brad,
6 I think I could use a little clarification
7 just for preparing for next week. We have
8 these various materials that have been
9 exchanged, so I would suggest that if this
10 seems right to you, that I'd circulate those
11 materials to the full Board.

12 And then the other thing, if I
13 could get clarification on is, it seems like
14 it would be helpful for someone to give the
15 Board -- we won't have any form of transcript
16 soon enough.

17 So it would be helpful if someone
18 could just give a summary presentation of this
19 discussion today to bring the Board up to date
20 beyond the papers that they would receive,
21 because I think the papers, by themselves,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 don't tell enough of the story of today. 109

2 And that would be a good way to
3 start the Board, I think, discussion next
4 week.

5 CHAIRMAN CLAWSON: Ted, I agree
6 wholeheartedly with you on that. I appreciate
7 you offering to send this out to the full
8 Board. Basically, to me, it looks like Mark's
9 already got his preparation to present to the
10 Board put together in his slide show there.

11 And, to me, John Stiver will just
12 have to bring us up to speed, but what I would
13 offer out to him is that we kind of condense
14 it a little bit and that we have not been able
15 to come to a conclusion at this Work Group
16 meeting, that there's too many uncertainties.

17 Basically, I'd suggest we allow
18 both sides to air their side of it, and put it
19 before the Board, and be able to proceed on
20 from there.

21 MR. KATZ: So again, I just want

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 to get a little more clarification about this¹¹⁰
2 though. I think John's always done a good job
3 at summarizing where we stand, but again --

4 MR. STIVER: Yes, I'll do it. I
5 can tweak my slides from the last time and,
6 kind of, update them to where we are now and -
7 -

8 MR. KATZ: Right. I think, you
9 know, John, given that, you know, we have
10 these other materials I'll distribute, I think
11 your summary really is to bring them up to
12 date with the discussion today.

13 And then, you know, certainly Paul
14 and Brad can chime in then with what they've
15 concluded from today at that point, but
16 somewhere in there I guess DCAS needs to have
17 its last words because it's going to go back
18 and think about some of the matters that it
19 tangled with today.

20 CHAIRMAN CLAWSON: Now, I want to
21 make a clarification on this because we're

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 only talking the time frame of '68 to '78,
111
2 correct?

3 MR. KATZ: That's correct.

4 CHAIRMAN CLAWSON: Okay. And my
5 suggestion would be to throw out, you know,
6 we're just looking at this area right now.
7 Fernald is a very, very big site. We've got
8 27, 28 slides we can go through, but I guess,
9 John, what I'm trying to get to the point of
10 is, we just looked at the '68 to '78, the --

11 MR. STIVER: Yes. I'll keep it to
12 that; focus to that time frame.

13 CHAIRMAN CLAWSON: Right.

14 MR. STIVER: I won't try to get
15 into anything else at this point.

16 MEMBER ZIEMER: And this is going
17 to really hinge on the thorium bioassay,
18 right?

19 MR. STIVER: This is all related
20 to the thorium bioassay.

21 MEMBER ZIEMER: Yes. So I think

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that's the focus. If you get too much beyond¹¹²
2 that, it's going to be very difficult for the
3 Board Members.

4 MR. STIVER: I won't try to do
5 that.

6 CHAIRMAN CLAWSON: And, John, I
7 can easily tell you that I cannot put anything
8 before the Board at this time because, to tell
9 you the truth, I don't got a clue where we're
10 at, other than I don't think we can really do
11 it.

12 So I appreciate you standing up
13 and taking that. And I believe that we owe it
14 to DCAS to be able to present their side of it
15 and proceed on, but we do need to get this new
16 material, Ted, out to the Board Members,
17 especially Mark's presentation, and so forth.

18 MR. KATZ: Right. This is Ted.
19 So I'll do that. And, John, if you want, I
20 think it would be good for you to send out
21 something in writing for the full Board. Send

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 it to me and I'll distribute it to everyone,¹¹³
2 also, please, to the petitioner.

3 And, you know, DCAS, Stu, whether
4 you want to send out some conclusory memo in
5 writing or just speak, but since you're
6 dealing with, you know, very little time, if
7 you wanted to speak to the Board, you know, in
8 real time, I think either would work.

9 The last thing I just want to
10 remind, we do have Sandra on the line, Brad,
11 and I think it would be good to give Sandra an
12 opportunity in case she has anything she wants
13 to say now to the Work Group.

14 CHAIRMAN CLAWSON: I agree
15 wholeheartedly. I appreciate that tip.

16 MS. BALDRIDGE: This is Sandra.
17 It's been interesting. I certainly appreciate
18 everybody's efforts, but, you know, some
19 questions can't be answered and I think we've
20 gotten to that point.

21 So I appreciate everybody's effort

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 on this on behalf of all those included in the
2 petition. And I'd like to thank you.

3 MR. KATZ: Very good. Thank you,
4 Sandra.

5 DR. MAURO: This is John. Just
6 one thing because it's plaguing me a bit.
7 Stu, it sounds like when we break, you're
8 going to get together with your crew and say,
9 is there a way we could wrestle this thing to
10 the ground and, you know, you're going to give
11 some thought to that.

12 I don't know whether you will be
13 able to or whether you will be able to between
14 now and next week, but is it possible that if
15 you folks come up with an ah-ha moment and
16 say, I think we got it. Is there any way, you
17 know, we could hear about it?

18 A concept, you don't have to solve
19 the whole thing. See, right now, I mean, I
20 haven't heard a strategy that could wrestle
21 this thing to the ground, but if you guys come

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 up with something, boy, we'd love to hear it₁₁₅

2 MR. HINNEFELD: Yes, John. If we
3 do have an ah-ha moment, we'll let you know.

4 MR. STIVER: Yes. Maybe we could
5 have a technical call, or something, before
6 the teleconference.

7 MR. HINNEFELD: Yes. That'll be a
8 little problematic for me, but we'll see what
9 we can do. I know next week is shot. I'm at
10 Lead Team retreat, NIOSH Lead Team retreat
11 next week, so I'll have to be working on this
12 either this weekend or nights if I'm going to
13 do anything on it.

14 But if we have something by then -
15 -

16 MR. STIVER: Okay. We'll be on
17 the lookout for it.

18 MR. HINNEFELD: -- we'll clue you
19 guys in. I can step out and get on a phone
20 call while I'm there.

21 CHAIRMAN CLAWSON: This is Brad

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 speaking again. Also, too, I'd kind of like ¹¹⁶
2 to preview both sides' response before the
3 Work Group meeting so that we're not doing it
4 -- or the Board Meeting.

5 I'd just like to see where we're
6 at because, hey, I have a very hard time
7 following some of this, but I'd still like to
8 be able to read through it and try to get an
9 understanding of where we're at on this.

10 So as the Work Group Chair, I
11 would like to be able to see the two
12 responses, at least a day or two before the
13 Board, if possible.

14 MR. KATZ: Yes, Brad, you'll
15 certainly have it from John Stiver, his
16 summary, I think, which will help you a lot.

17 CHAIRMAN CLAWSON: Well, I'd also
18 like to see DCAS' too because I'm just trying
19 to get the feel. If anything does change to
20 it, Mark. If it doesn't change, you know,
21 that's fine too. So that I can try to digest

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

1 it.

117

2 It's probably not uncommon, but I
3 talked to people that can help me understand
4 it in a more basic form. It's been said, you
5 know, I'm not the most scientific. I'd
6 appreciate that. If something does change,
7 that we're kept notified before the Board
8 Meeting.

9 MR. HINNEFELD: Yes, we'll give it
10 a shot.

11 CHAIRMAN CLAWSON: Okay. Thank
12 you, Stu. I don't see anything else on the
13 agenda so is there anything else that needs
14 more to be said or that we need to discuss as
15 a Work Group? I guess, Dr. Ziemer?

16 MEMBER ZIEMER: No. I think it's
17 time to adjourn.

18 CHAIRMAN CLAWSON: Thank you. I
19 appreciate that. Is there anybody else on
20 here that has something that they need to say?

21 I appreciate Sandra making her comments. I

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 know Ray's on here too, but if there's anybody
2 else that wants to have something clarified or
3 say, I guess, at this time, I'd give that
4 opportunity.

5 If not hearing anything, then,
6 Ted, I guess I give a motion to adjourn this
7 Work Group meeting.

8 MR. KATZ: And I think Paul
9 seconds you, so we are adjourned.

10 CHAIRMAN CLAWSON: I'd like to
11 thank everybody for the time they've spent on
12 this. I know that it's been difficult. Thank
13 you.

14 (Whereupon, the meeting in the
15 above-entitled matter was concluded at 1:07
16 p.m.)

17
18
19
20
21

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

This transcript of the Advisory Board on Radiation and Worker Health, Fernald Work Group, has been reviewed for concerns under the Privacy Act (5 U.S.C. § 552a) and personally identifiable information has been redacted as necessary. The transcript, however, has not been reviewed and certified by the Chair of the Fernald Work Group for accuracy at this time. The reader should be cautioned that this transcript is for information only and is subject to change.

1
2
3
4
5

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701